PEMBROLIZUMAB AS A NEW, FIRST-LINE STANDARD OF CARE IN COLORECTAL CANCER
Updated results of the pivotal phase III Keynote 177 trial confirm that pembrolizumab is associated with a significantly longer progression free survival and a higher response rate compared to chemotherapy in the first line treatment of patients with microsatellite instability-high, mismatch repair deficient (MSI-H-dMMR) metastatic colorectal cancer (CRC)…
A SHORT COURSE OF RADIOTHERAPY WITH LONGER NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER
Results of the phase III RAPIDO trial identify a short-course radiotherapy (5×5 Gy over 8 days) followed by either 6 cycles of CAPOX or 9 cycles of FOLFOX4 and a total mesorectal excision (TME) as a new standard of care for patients with locally advanced rectal cancer. Compared to the current standard of care, this new strategy proved to be associated with a significant reduction in the rate of treatment failure…
FIRST-IN-HUMAN TRIAL OF THE ATR INHIBITOR BAY 1895344 SHOWS PROMISING ANTITUMOUR ACTIVITY IN PATIENTS WITH ADVANCED SOLID TUMOURS
ATR kinase inhibition in preclinical tumour models is known to inhibit tumour growth. In the presented phase I trial, the ATR inhibitor BAY 1895344 was able to induce durable partial responses in a proportion of heavily pretreated patients with solid tumours harbouring defects in the DNA damage repair cascade…
DURVALUMAB PLUS PLATINUM-ETOPOSIDE SHOWS SIGNIFICANT OVERALL SURVIVAL IMPROVEMENT IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Updated results of the phase III CASPIAN trial confirm the previously reported survival benefit obtained from adding durvalumab to platinum-etoposide in the first line treatment of patients with extensive-stage small cell lung cancer patients. The further addition of tremelimumab did not lead to an improved outcome…
MATERNAL CANCER TRANSMISSION VIA TUMOUR-CONTAMINATED VAGINAL FLUID ASPIRATION DURING TRANSVAGINAL DELIVERY
Transmission of maternal cancers to their child is extremely rare, occurring in approximately 0.2% of mothers with active cancer. Recently, investigators of the TOP GEAR trial reported on two suspected cases of direct vaginal transmission of cervical cancer cells to the lungs, likely due to the aspiration of tumour-contaminated vaginal fluid during delivery…
Top
